TY - JOUR
T1 - Chemotherapy resistance in osteosarcoma
T2 - Current challenges and future directions
AU - Chou, Alexander J.
AU - Gorlick, Richard
PY - 2006/7/1
Y1 - 2006/7/1
N2 - For patients with osteosarcoma, the use of chemotherapy has improved survival from 11% with surgical resection alone in the 1960s, to 70% by the mid-1980s. However, survival has since plateaued, despite advances in anticancer therapy. Elucidation of the mechanisms of chemoresistance and implementation of strategies to overcome chemoresistance will likely be pivotal to improving survival. In this review, the focus is on the current understanding of the mechanisms of resistance to the most commonly used agents in the treatment of osteosarcoma and the methods employed to overcome chemotherapy resistance.
AB - For patients with osteosarcoma, the use of chemotherapy has improved survival from 11% with surgical resection alone in the 1960s, to 70% by the mid-1980s. However, survival has since plateaued, despite advances in anticancer therapy. Elucidation of the mechanisms of chemoresistance and implementation of strategies to overcome chemoresistance will likely be pivotal to improving survival. In this review, the focus is on the current understanding of the mechanisms of resistance to the most commonly used agents in the treatment of osteosarcoma and the methods employed to overcome chemotherapy resistance.
KW - Chemotherapy resistance
KW - Molecular mechanisms
KW - Novel therapies
KW - Osteosarcoma
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=33746450466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746450466&partnerID=8YFLogxK
U2 - 10.1586/14737140.6.7.1075
DO - 10.1586/14737140.6.7.1075
M3 - Review article
C2 - 16831079
AN - SCOPUS:33746450466
SN - 1473-7140
VL - 6
SP - 1075
EP - 1085
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 7
ER -